VolitionRx is developing two
types of non-invasive cancer diagnostic tests based on its patented
Nucleosomics® technology. The company’s overarching goal is to bring to market
its cancer blood tests and revolutionize cancer diagnosis.
While VolitionRx’s current
focus is on the detection of colorectal cancer, future plans call for expansion
into detection of various other cancers as well. Following ongoing clinical
trials and regulatory approval, the company plans to offer its tests for
individualized cancers under the NuQ® brand.
Backed by a scientific
advisory board comprised of scientists from Europe, Asia, and the United
States, VolitionRx is boldly progressing in the development of its cancer test,
and in the next year expects to begin to get the results from its ongoing
clinical trial involving 16,000 patients.
In the near future, the
company also anticipates receiving legal approval to sell its test in Europe,
as well as start the process of U.S. FDA trials. Furthermore, VolitionRx looks
forward to the second half of the year, at which time management hopes to
uplist the company’s stock to a major exchange.
For more information, visit
www.volitionrx.com or www.nucleosomics.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
